Menu

Press Releases

KEYTRUDA® (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress

, , ,

Results from KEYNOTE-010 Include Improved Patient-Reported Health-Related Quality of Life Outcomes and 18-Month Findings of Overall Survival and Progression-Free Survival in Previously Treated Patients Whose Tumors Express PD-L1 (Tumor Proportion Score of One Percent or More) KENILWORTH, N.J. October 9, 2016 –(BUSINESS WIRE)– Merck (NYSE:MRK), known as MSD outside the United States and Canada, today […]

FDA grants breakthrough therapy designation for Roche’s Actemra/RoActemra in giant cell arteritis, a form of vasculitis

, , ,

Roche recently announced positive results from a Phase III GCA clinical trial Fourteenth Breakthrough Therapy designation for Roche medicines There have been no therapies approved for GCA in more than 50 years Basel, 05 October 2016 – Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted […]

Sanofi and Regeneron Announce Positive Dupixent® (dupilumab) Phase 3 Atopic Dermatitis Data Published in The New England Journal of Medicine​

, , ,

Data to be presented today during a late breaking abstract session at the 25th Annual European Academy of Dermatology and Venereology (EADV) Congress Paris, France and Tarrytown, N.Y. (October 1, 2016) – Sanofi and Regeneron Pharmaceuticals, Inc. today announce that detailed results from LIBERTY AD SOLO 1 and SOLO 2, two placebo-controlled Phase 3 studies […]

Cigna Telehealth Connection Expands Access and Choice to Millions, Including Adding Access to Behavioral Health Consults

,

BLOOMFIELD, Conn, (Sept. 27, 2016) — Global health service company Cigna (NYSE: CI) today announced new, expanded access and choice to affordable telehealth services for millions of Americans enrolled in Cigna administered medical and behavioral health plans for 2017. In 2017, Cigna will significantly expand its telehealth coverage by adding AMWELL (by American Well) to […]

Inovalon and MDLIVE Bring Real-Time Advanced Analytics to Telemedicine Marketplace

,

On-Demand, Real-Time Patient Insights and Analytics to Drive High-Value Impact for Telemedicine Visits BOWIE, Md, (Sept. 12, 2016) — Inovalon (NASDAQ: INOV), a leading technology company providing advanced, cloud-based analytics and data-driven intervention platforms to the healthcare industry, today announced a multi-year agreement with MDLIVE, a leading telehealth platform provider, to provide on-demand, real-time patient […]

WakeMed and UNC School of Medicine Teaching Renew Agreement

RALEIGH, N.C. (September 7, 2016) – For more than 45 years, WakeMed Health & Hospitals and the UNC School of Medicine have worked together to teach medical students and residents. This longstanding collaboration continues as WakeMed and the UNC School of Medicine have entered into a new 10-year agreement to provide education and training to […]

Navidea Biopharmaceuticals Enters into Letter of Intent with Cardinal Health for the Sale of Lymphoseek® in North America

, , ,

Navidea retains rights to non-competitive diagnostic indications and all therapeutic applications DUBLIN, Ohio–(BUSINESS WIRE)–Sep. 6, 2016– Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that it has executed a Letter of Intent (“LOI”) with Cardinal Health, Inc. (NYSE:CAH) for the sale of all rights, title and interest to Navidea’s Lymphoseek product for all FDA-approved, pending and […]

Danaher To Acquire Cepheid For $53.00 Per Share, Or Approximately $4 Billion

, ,

WASHINGTON, Sept. 6, 2016 /PRNewswire/ — Danaher Corporation (NYSE:DHR) (“Danaher” or the “Company”) announced today that it has entered into a definitive merger agreement with Cepheid (NASDAQ:CPHD) pursuant to which Danaher will acquire all of the outstanding shares of Cepheid for $53.00 per share in cash, or a total enterprise value of approximately $4 billion […]

Phase III study showed Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy

, , , ,

TECENTRIQ showed significant improvement in overall survival for people regardless of their PD-L1 status Data will be discussed with global health authorities, including the U.S. Food and Drug Administration (FDA) September 1, 2016 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results for TECENTRIQ® from the Phase III study, OAK. The study met […]

Fighting Prescription Drug Misuse through Community Programs: Cardinal Health Foundation Announces Generation Rx Medication Disposal Grants

, , ,

DUBLIN, Ohio, Aug. 31, 2016 /PRNewswire/ — Non-profit organizations across the country were awarded grants from the Cardinal Health Foundation to help fight prescription drug misuse by improving their communities’ medication disposal programs. According to the 2013 National Survey on Drug Use and Health, nearly 70% of those who misuse prescription drugs get them from […]

«‹ 72 73 74 75›»